GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

Table 2 Results of planned meta-analyses with random effects

Outcome	Trials (n)	Estimate (HR)	95% CI	P value of HR	I² (%)	P value of I²
MACE
All	8	0.86	0.79–0.94	0.006	50.0	0.080
Prior CVD	6	0.84	0.79–0.90	< 0.001	6.1	0.370
No prior CVD	6	0.94	0.83–1.06	0.330	0.0	0.420
CV mortality	8	0.87	0.78–0.96	0.016	18.7	0.330
Non-fatal MI	8	0.91	0.81–1.01	0.078	34.6	0.170
Non-fatal stroke	8	0.84	0.76–0.94	0.007	0.0	0.580
Heart failure	8	0.90	0.83–0.98	0.023	0.0	0.670
All-cause mortality	8	0.88	0.80–0.96	0.012	26.3	0.350
Renal endpoints	6	0.83	0.73–0.94	< 0.012	36.5	0.280
New macro	6	0.74	0.67–0.82	< 0.001	11.0	0.370

ISSN: 1475-2840